Our science is visionary.
Our commitment is relentless.
preserve vision and
prevent blindness.
About Us
Qlaris Bio is a clinical stage biotechnology company founded on a relentless commitment to develop innovative first-in-class therapies that can make a truly impactful change for patients suffering from serious and debilitating ophthalmic diseases.
Our Approach
We are exploring novel mechanisms of action to address the largest unmet needs in ophthalmology.
Our Science
Our lead asset, QLS-111, has a unique mechanism of action designed to lower intraocular pressure (IOP) by relaxing vessels of the vascular and vascular-like tissues distal to the trabecular meshwork, thereby reducing distal outflow resistance and lowering EVP.
By reducing EVP and distal outflow resistance, QLS-111 has the potential to enable the achievement of lower IOP targets than available therapies currently allow.
QLS-111 is currently in development for the treatment of Normal Tension Glaucoma, Primary Open-Angle Glaucoma, Ocular Hypertension, and elevated IOP associated with rare diseases such as Sturge-Weber Syndrome.
Recent News See All News
Qlaris Bio to present new clinical and preclinical data on QLS-111 at 2025 World Glaucoma Congress
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass. — June 23, 2025 — Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be presented […]
Qlaris Bio announces development of fixed-dose combination therapy with QLS-111 and latanoprost for the treatment of glaucoma
Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass. — June 11, 2025 — Qlaris Bio, Inc., a clinical-stage biotechnology company, today announced that it is developing a novel preservative-free, fixed-dose combination (FDC) therapy that combines the company’s lead program, QLS-111, and […]